Hepagene
Hepagene.com
ABOUT HEPAGENE
Non-alcoholic Steatohepatitis (NASH)
Chronic Hepatitis B Infection (HBV)
PIPELINE
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
About HPG1860
About NASH
About Hepagene Therapeutics, Inc
MANAGEMENT TEAM
ABOUT
+
THERAPEUTIC FOCUS
PIPELINE
NEWS
CAREERS
CONTACT
CONTACT US
For further information, please contact:
investor@hepagene.com
